Matushansky Igor 4

4 · HOOKIPA Pharma Inc. · Filed Jan 12, 2022

Form 4

Period: 2021-12-21

Chief Medical Officer

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−11,366→ 2,842 total
Exercise: $0.10Exp: 2026-12-31→ Common Stock (11,366 underlying)
Sale
Common Stock
2021-12-21$2.49/sh−5,304$13,207→ 80,178 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−3,408→ 4,261 total
Exercise: $0.10Exp: 2026-12-31→ Common Stock (3,408 underlying)
Exercise/Conversion
Common Stock
2021-12-21$0.10/sh+3,408$341→ 87,512 total
Sale
Common Stock
2021-12-21$2.49/sh−2,205$5,490→ 85,307 total
Exercise/Conversion
Common Stock
2021-12-21$0.10/sh+8,079$808→ 85,482 total
Sale
Common Stock
2021-12-21$2.49/sh−7,440$18,526→ 84,104 total
Exercise/Conversion
Stock Option (Right to Buy)
2021-12-21−8,079→ 0 total
Exercise: $0.10Exp: 2026-12-31→ Common Stock (8,079 underlying)
Exercise/Conversion
Common Stock
2021-12-21$0.10/sh+11,366$1,137→ 91,544 total

Footnotes (4)

[F1]The sales reported on this Form 4 were in connection with the satisfaction of tax obligations and the shares retained upon exercise remain subject to a lockup agreement which expires on March 8, 2021.
[F2]25% of this option vested and became exercisable on March 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 129,212 shares and the Reporting Person has exercised his option to purchase 129,212 shares.
[F3]25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 45,466 shares and the Reporting Person has exercised his option to purchase 42,624 shares.
[F4]25% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 13,634 shares and the Reporting Person has exercised his option to purchase 9,373 shares.

Documents

1 file